Analysts Offer Predictions for ADCT FY2026 Earnings

ADC Therapeutics SA (NYSE:ADCT) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of ADC Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($2.10) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share.

ADC Therapeutics (NYSE:ADCT) last issued its earnings results on Wednesday, May 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The firm had revenue of $23.03 million during the quarter, compared to analysts’ expectations of $17.71 million.

Other equities analysts have also issued research reports about the company. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 target price on shares of ADC Therapeutics in a research note on Thursday, May 15th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of ADC Therapeutics in a research note on Monday, March 31st. Guggenheim reduced their target price on ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 31st. Finally, Stephens increased their price target on ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, ADC Therapeutics presently has a consensus rating of “Buy” and an average target price of $7.75.

ADC Therapeutics Price Performance

Shares of ADCT stock opened at $3.66 on Wednesday. The firm has a market capitalization of $362.99 million, a price-to-earnings ratio of -1.53 and a beta of 1.96. The business has a fifty day moving average of $1.95 and a 200 day moving average of $1.87. ADC Therapeutics has a 1 year low of $1.05 and a 1 year high of $4.13.

Institutional Investors Weigh In On ADC Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADCT. SG Americas Securities LLC grew its position in ADC Therapeutics by 35.6% during the 4th quarter. SG Americas Securities LLC now owns 36,140 shares of the company’s stock worth $72,000 after purchasing an additional 9,483 shares during the period. Rhumbline Advisers grew its position in ADC Therapeutics by 15.6% during the 4th quarter. Rhumbline Advisers now owns 110,037 shares of the company’s stock worth $219,000 after purchasing an additional 14,848 shares during the period. Bank of New York Mellon Corp grew its position in ADC Therapeutics by 6.0% during the 4th quarter. Bank of New York Mellon Corp now owns 171,993 shares of the company’s stock worth $342,000 after purchasing an additional 9,750 shares during the period. Intech Investment Management LLC grew its position in shares of ADC Therapeutics by 195.7% during the 4th quarter. Intech Investment Management LLC now owns 38,435 shares of the company’s stock valued at $76,000 after acquiring an additional 25,437 shares during the period. Finally, Platinum Investment Management Ltd. increased its stake in shares of ADC Therapeutics by 11.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 1,612,556 shares of the company’s stock valued at $3,209,000 after purchasing an additional 168,040 shares in the last quarter. 41.10% of the stock is owned by institutional investors and hedge funds.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.